ICON partners with US Government for clinical trials of Covid-19 vaccines

14 Sep 2023
www.pharmaceutical-technology.com
VaccineClinical StudyImmunotherapy
ICON partners with US Government for clinical trials of Covid-19 vaccines
Preview
Source: Pharmaceutical Technology
Phalguni Deswal
@Phalguni_GD
ICON partners with US Government for clinical trials of Covid-19 vaccines
Preview
Source: Pharmaceutical Technology
The US government has plans to invest over $5bn in the Project NextGen programme. Image Credit: PopTika / Shutterstock.
US Biomedical Advanced Research and Development Authority (BARDA) has partnered with Ireland-based ICON to conduct clinical trials of Covid-19 vaccine candidates selected as part of “Project NextGen”.
A part of the US Government’s Strategic Preparedness and Response division, BARDA has launched Project NextGen to develop Covid-19 vaccines and therapies for current and future strains. To achieve this, BARDA plans to leverage its public-private partnerships. The government has plans to invest more than $5bn in the Project NextGen programme.
Recommended Reports
ICON partners with US Government for clinical trials of Covid-19 vaccines
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - PBMC vaccine in Vaginal Cancer GlobalData
ICON partners with US Government for clinical trials of Covid-19 vaccines
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - PBMC vaccine in Penile Cancer GlobalData
View allCompanies IntelligenceICON PlcEmergent BioSolutions IncRegeneron GmbHThe U.S. governmentView all
In June, the European Medicines Agency (EMA) identified the need to update the Covid-19 vaccines to include the XBB Omicron variant. The US Government seconded that sentiment, and last month, BARDA partnered with Regeneron to develop a Covid-19 monoclonal antibody vaccine candidate.
ICON’s government and public health solutions team will conduct a Phase IIb active comparator clinical trial to evaluate the efficacy of the next-generation Covid-19 vaccineCovid-19 vaccine, selected by BARDA, compared to the currently approved/authorised vaccines. The trial is expected to enrol 10,000 volunteers over a six-month period.
Although the Covid-19 trial activity has significantly decreased in the last two years, several trials have been initiated in 2023. As per GlobalData’s clinical trial database, more than 80 trials have been initiated for Covid-19 indication in the US and over 400 trials globally this year.
GlobalData is the parent company of Pharmaceutical Technology.
ICON previously partnered with Evergreen Therapeutics to develop a Covid-19 drug therapy in 2021. The Ireland-based company also has a patent engagement platform that increased patient outreach and enrolment.
ICON has previously partnered with BRADA to conduct a clinical trial for an anthrax vaccine, AV7909. The vaccine comprises Emergent BioSolutions’s Biothrax combined with an immune system stimulant or adjuvant.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.